Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells

With increasing clinical demands for MEK inhibitors in cancer treatment, overcoming the resistance to MEK inhibitors is an urgent problem to be solved. Numerous reports have shown that MEK inhibition results in the activation of PI3K-Akt signaling, which may confer apoptotic resistance to MEK inhibitors. We here demonstrate that the blockade of the mevalonate pathway using the antilipidemic drug statins represses Akt activation following MEK inhibition and induces significant apoptosis when co-treated with CH5126766 or trametinib. These events were clearly negated by the addition of mevalonate or geranylgeranyl pyrophosphate, indicating that the protein geranylgeranylation is implicated in the apoptotic resistance to MEK inhibitors. Furthermore, mechanistically, the combined treatment of CH5126766 with statins upregulated TNF-related apoptosis-inducing ligand (TRAIL), which was dependent on inhibition of the mevalonate pathway and is involved in apoptosis induction in human breast cancer MDA-MB-231 cells. The present study not only revealed that the mevalonate pathway could be targetable to enhance the efficacy of MEK inhibitors, but also proposes that combinatorial treatment of MEK inhibitors with statins may be a promising therapeutic strategy to sensitize cancer cells to apoptosis.

[1]  Chia-Hung Chen,et al.  MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK‐mediated HER2 phosphorylation at Thr701 , 2017, Molecular oncology.

[2]  T. Sakai,et al.  Molecular‐targeting therapies against quantitative abnormalities in gene expression with malignant tumors , 2017, Cancer science.

[3]  A. Giobbie-Hurder,et al.  Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Prados,et al.  Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas , 2016, Oncotarget.

[5]  Bin Fang,et al.  Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer , 2016, Molecular Cancer Research.

[6]  M. Nishimura,et al.  Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer. , 2016, Cancer discovery.

[7]  B. Levine,et al.  Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic. , 2016, Cell reports.

[8]  M. Aoki,et al.  ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor , 2015, Molecular Cancer Therapeutics.

[9]  O. Wolkenhauer,et al.  Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures , 2015, Nucleic acids research.

[10]  M. Prados,et al.  EGFR blockade prevents glioma escape from BRAFV600E targeted therapy , 2015, Oncotarget.

[11]  J. Engelman,et al.  The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. , 2015, Cancer discovery.

[12]  E. Jokinen,et al.  MEK and PI3K inhibition in solid tumors: rationale and evidence to date , 2015, Therapeutic advances in medical oncology.

[13]  M. Horinaka,et al.  The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells , 2014, PloS one.

[14]  L. Murray,et al.  Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Ahern,et al.  Statins and breast cancer prognosis: evidence and opportunities. , 2014, The Lancet. Oncology.

[16]  S. Lowe,et al.  Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. , 2014, Cancer cell.

[17]  M. Herlyn,et al.  On the TRAIL to overcome BRAF-inhibitor resistance. , 2014, The Journal of investigative dermatology.

[18]  A. Berger,et al.  RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. , 2014, The Journal of investigative dermatology.

[19]  J. Hou,et al.  Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells , 2013, Cell Death and Disease.

[20]  N. Rosen,et al.  Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. , 2013, Cancer research.

[21]  J. Engelman,et al.  MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. , 2012, Cancer research.

[22]  F. Bertucci,et al.  Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target , 2012, Stem cells.

[23]  I. Marschner,et al.  Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus , 2012, Clinical Cancer Research.

[24]  Andrew J. Brown,et al.  Akt acutely activates the cholesterogenic transcription factor SREBP-2. , 2012, Biochimica et biophysica acta.

[25]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[26]  J. Holbrook,et al.  Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212 , 2011, Molecular Cancer Therapeutics.

[27]  J. Meyerhardt,et al.  Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. , 2011, The Journal of clinical investigation.

[28]  Heung Tae Kim,et al.  A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.

[29]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[30]  T. Satou,et al.  Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway , 2010, Journal of experimental & clinical cancer research : CR.

[31]  B. Taylor,et al.  Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). , 2010, Cancer research.

[32]  R. Karlsson,et al.  Rho GTPase function in tumorigenesis. , 2009, Biochimica et biophysica acta.

[33]  Laura M. Heiser,et al.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.

[34]  S. Miyamoto,et al.  Focal Adhesion Kinase as a RhoA-activable Signaling Scaffold Mediating Akt Activation and Cardiomyocyte Protection* , 2008, Journal of Biological Chemistry.

[35]  Jing Xu,et al.  Sp1-mediated TRAIL induction in chemosensitization. , 2008, Cancer research.

[36]  A. Ridley,et al.  Rho GTPases in cancer cell biology , 2008, FEBS letters.

[37]  P. Hersey,et al.  Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1 , 2007, Clinical Cancer Research.

[38]  M. Koyuturk,et al.  Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. , 2007, Cancer letters.

[39]  Julian Downward,et al.  PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP , 2005, Oncogene.

[40]  J. Harper,et al.  Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). , 2005, Cell metabolism.

[41]  F. Appelbaum,et al.  Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. , 2004, Blood.

[42]  S. Grant.  Reducing cholesterol and overcoming drug resistance , 2004 .

[43]  M. Minden,et al.  HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.

[44]  E. Sahai,et al.  RHO–GTPases and cancer , 2002, Nature Reviews Cancer.

[45]  J. Gutkind,et al.  Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-κB , 2002, Oncogene.

[46]  J. Soria,et al.  Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. , 2001, Carcinogenesis.

[47]  L. Altucci,et al.  Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL , 2001, Nature Medicine.

[48]  D. Catovsky,et al.  Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice , 1998, British journal of haematology.

[49]  K. Keyomarsi,et al.  Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. , 1991, Cancer research.

[50]  G. Batist,et al.  Use of statins and the risk of death in patients with prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  W. Sellers,et al.  Cancer esearch apeutics , Targets , and Chemical Biology 3 CA Mutation Uncouples Tumor Growth and Cyclin D 1 R ulation from MEK / ERK and Mutant KRAS Signaling , 2010 .